NCT05957198View on ClinicalTrials.gov

Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease

CompletedOBSERVATIONAL
Enrollment

114,921

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

September 26, 2023

Study Completion Date

September 26, 2023

Conditions
Lung Diseases, Interstitial
Trial Locations (1)

06877

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05957198 - Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease | Biotech Hunter | Biotech Hunter